Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18049985 | 0.85 | SMN1; SMN2 (0.54) | L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL10282273 | 0.84 | LMNA (0.62) | L3MBTL1LMNAPOLBGAASMN1; SMN2 | |
| SCHEMBL5709109 | 0.84 | L3MBTL1 (0.60) | L3MBTL1LMNAPOLBNAAAGAA | |
| SCHEMBL5638909 | 0.83 | EPHX2 (0.57) | POLB | |
| SCHEMBL31185928 | 0.83 | NPC1 (0.54) | L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL31186198 | 0.83 | CYP1A2 (0.50) | LMNAPOLB | |
| SCHEMBL3101975 | 0.83 | LOXL2 (0.43) | L3MBTL1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL31185802 | 0.83 | CYP1A2 (0.60) | L3MBTL1LMNAGAASMN1; SMN2 | |
| SCHEMBL19755858 | 0.82 | SMN1; SMN2 (0.54) | L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL668703 | 0.82 | L3MBTL1 (0.59) | L3MBTL1LMNAPOLBGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118851960-A | Synthesis method of N- (2- (methylsulfonyl) ethyl) amide compound | 南昌大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-3205642-B1 | ANILINE INTERMEDIATE FOR THE PREPARATION OF AN AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE. | MITSUI CHEMICALS AGRO INC (JP) | 2022-03-23 | — | — | EP | disclosed |
| CN-105732414-B | The method of control of amide derivatives, the noxious organism control agent containing the amide derivatives and harmful organism | 三井化学AGRO株式会社 | 2019-05-03 | — | — | CN | disclosed |
| CN-105061251-B | Anil | 三井化学AGRO株式会社 | 2019-04-19 | — | — | CN | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-2121637-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | Smithkline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-0339976-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-5238962-A | Administering an antidepressants | HOFFMANN-LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0339976-A1 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |